ALGN · Q3 2025 Earnings

Cautious

Align Technology

Reported October 29, 2025

30-second summary

30-second take: Revenue of $995.7M (+1.8% YoY) beat the $965–985M guide ($10.7M above the top of the range / $20.7M above midpoint), Clear Aligner volume re-accelerated to +4.9% YoY (vs. +0.3% in Q2), and management raised FY25 Clear Aligner volume growth from "low-single" to "mid-single" digits while narrowing GAAP operating margin guidance to 13.6–13.8% (midpoint +20bps vs. prior 13–14%). But ASP fell another $5 sequentially to $1,245, GAAP operating margin of 9.7% missed its own 10.5–11.5% guide, and management explicitly refused to bridge the FY26 "≥100bps margin improvement" promise to a top-line number when pressed. The volume reset is real; the structural North America retail problem and the 2026 reconciliation are not.

Headline numbers

EPS

Q3 FY2025

$2.61

Revenue

Q3 FY2025

$1.00B

+1.8% YoY

Gross margin

Q3 FY2025

64.2%

Operating margin

Q3 FY2025

9.7%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$1.00B	+1.8%	$1.01B	-1.6%
EPS	$2.61	—	$2.49	+4.8%
Gross margin	64.2%	—	69.9%	-570bps
Operating margin	9.7%	—	16.1%	-640bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q3 FY2025	$965 million to $985 million	$995.7 million	+$10.7M to +$30.7M above guide	Beat
GAAP Gross Margin	Q3 FY2025	64% to 65%	64.2%	+0.2 pts above guide (bottom of range)	Beat
Non-GAAP Gross Margin	Q3 FY2025	Flat from Q2'25	~71.0%	In-line with qualitative guidance	Beat
GAAP Operating Margin	Q3 FY2025	10.5% to 11.5%	9.7%	-0.8 pts below guide (bottom of range)	Missed
Non-GAAP Operating Margin	Q3 FY2025	Approximately 22%	23.9%	+1.9 pts above guide	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	Q4 FY2025	$1,025 million to $1,045 million	—
Clear Aligner volume	Q4 FY2025	Expected up sequentially	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Clear Aligner volume growth	FY2025	Low-single digits	Mid-single digits	Upward revision: low-single → mid-single digits	Raised
GAAP Operating Margin	FY2025	13% to 14%	13.6% to 13.8%	+0.6 to +0.8 pts at midpoint	Raised
Capital Expenditures	FY2025	$100 million to $125 million	Approximately $100 million	-$0 to -$25M (narrowed to midpoint)	Lowered

Reaffirmed unchanged this quarter: Revenue growth (Flat to slightly up from 2024), Non-GAAP Operating Margin (Slightly above 22.5%)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Clear Aligner	$0.806B	+2.4%
Imaging Systems and CAD/CAM Services	$0.19B	-0.6%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Clear Aligner Volume	647.8 thousand cases
Clear Aligner Volume YoY Growth	4.9%
Clear Aligner Volume QoQ Growth	0.5%
Teens and Kids Clear Aligner Volume	256.0 thousand cases
Teens and Kids Volume YoY Growth	8.3%
Teens and Kids Volume QoQ Growth	14.7%
Clear Aligner Revenue Per Case Shipment	$1,245
Non-GAAP Operating Margin	23.9%

Management tone

Q1 anchor unknown → Q2 restructuring pivot → Q3 cautious operational stabilization with persistent NA retail concession.

The growth narrative remains replaced by a managed-decline-plus-restructuring narrative, but with a sliver of stabilization. Last quarter management announced $150–170M of restructuring charges and reframed the company as one resizing to revenue reality. This quarter the language is "we are nearing completion of the restructuring actions" — execution-mode rather than announcement-mode — and the volume guide raise gives management a small concrete data point to point to. But the framing of FY26 margin improvement is still entirely contingent: "we expect these restructuring actions as well as other initiatives to improve our GAAP and non-GAAP operating margins by at least 100 basis points year over year." Margin expansion is sourced from cost-out, not operating leverage on growth.

The North America retail diagnosis hardened from "weak" to "structurally bifurcated." In Q2 management called out North America, France, and Germany as concentrated weakness. This quarter the framing tightened: DSO is delivering "continued strong double-digit year-over-year growth" (Joe Hogan said 20%+ in some areas of North America DSO), while the retail doctor channel is explicitly "mixed." Pressed by Baird's Jeff Johnson on whether gross receipts or CCA showed any sequential improvement, management confirmed no material change, no improvement, no deterioration — the retail channel is stuck. Piper's Jason Bednar got management to reframe this as DSOs winning via digital scanning, visualization, financing, and competitive pricing — which is to say, the retail doctors are losing the patient inside their own chairs.

The pricing posture shifted from "ASPs down on mix" to "ASPs down on mix and we can't tell you when that reverses." Stifel's John Block pressed on the QoQ ASP decline despite prior expectation of an increase; management's answer was that China's lower ASP became a larger share of Q3 mix and that Q4 should reverse as Europe's share grows. That's a quarter-to-quarter geography rotation, not a pricing thesis. The $30 YoY ASP decline is more telling — discounts and lower-priced country mix are persistent, not transitional.

Management refused to reconcile the 2026 math when handed the opportunity. Joe Hogan (Stifel) explicitly laid out the bear case: half the Clear Aligner business growing double-digits, half flat-to-down in North America, ASPs under pressure — pointing to low-single-digit overall growth, which makes 100bps margin expansion entirely cost-driven. Management's response: reiterated the 5–15% long-term LRP range and declined to provide 2026 specifics. That was the cleanest tell of the call. If the 2026 plan reconciled, management would have walked through it.

Recurring themes management leaned on this quarter:

Digital workflow innovation and AI-powered treatment planning as competitive moatInternational growth (EMEA, APAC, Latin America) offsetting North American retail weaknessDSO channel outperformance and strategic relianceTeens and kids segment as high-growth categoryRestructuring and operational efficiency initiativesProduct innovation velocity (ClinCheck Live Plan, ExoCAD ART, Invisalign Pallet Expander)

Risks management surfaced:

North American retail doctor channel remains mixed with lower volumesProduct mix shift to lower-priced countries and products impacting ASPForeign exchange headwinds and macroeconomic conditionsUS tariff actions and regulatory changesDeferred revenue decline year-over-year ($78.7M decrease, 6.2% YoY)

Q&A highlights

John Block · Stifel

ASP was down QoQ despite expectation of increase; seeking clarification on geographic mix impact, Q4 ASP outlook, pricing environment, and timing of no-refinement plan rollout

ASP decline driven by China's lower ASP becoming larger percentage of mix in Q3; Q4 will reverse as Europe becomes larger and China smaller. No-refinement plan is continuous evolution (5x5 to 3x3 to moderate products) reflecting improved technology and doctor confidence, not a phase transformation.

Q3 ASP decline due to geographic mix shift (China lower ASP, Europe higher ASP)Q4 expected to show ASP improvement as geographic mix reversesNo-refinement plan evolved from 5x5 to 3x3 to moderate products with ~1 aligner per caseDoctors gaining optionality: proceed without refinements, purchase 1 if needed, or buy insurance policy

Jeff Johnson · Baird

Confirmation of double-digit YoY growth in EMEA and APAC; request for specific percentages to back into North America performance; inquiry into gross receipts vs case closure dynamics and whether behavior improved/deteriorated through Q3

Confirmed robust double-digit growth across EMEA and APAC with strength in India, Turkey, and other markets; declined to provide specific percentages. Gross receipts and CCA data show no material change or primary change in North American retail dynamics; situation consistent quarter-to-quarter, no improvement or deterioration.

Top 10 countries up YoY, with India and Turkey performing wellDouble-digit growth described as 'robust in a lot of different parts of the world'No material change in gross receipts vs case closure dynamics in North AmericaNorth America retail remains challenged; DSO segment continues strong growth

Joe Hogan · Stiefel

High-level discussion on 2026 margin targets (100 bps improvement) and directional top-line guidance; concern that clear aligner business split (half double-digit growth, half flat-to-down in North America) and ASP headwinds point to low single-digit overall growth

Reiterated 5-15% long-term growth targets without confirming 2026-specific guidance. Highlighted robust Q3 with 9 of top 10 countries up. Acknowledged North America retail as 'biggest issue' but North America DSO showing 20%+ growth. Declined to make 2026 predictions.

5-15% long-term growth target maintained, unchanged from LRPQ3: 9 of top 10 countries showed growthNorth America DSO growth exceeds 20% in some areasNorth America retail identified as main headwind

Michael Cherney · Lyric Partners

What is the biggest gating factor preventing North America retail customers from returning to normalized demand, and what can Align proactively do beyond waiting for macro improvement?

Primary gating factor is consumer economic confidence, which affects retail customers more than business-oriented DSOs. Proactive measures include: pushing DSO model (proven to work with GPs and orthos), downstream marketing (zip code targeting), brand leverage, technology portfolio, and direct sales force engagement to help retail customers and doctors. Cannot rely on macro improvement alone.

North America retail and DSO segments have differential pressure; Canada experienced more pressure than U.S.Retail customers more economically sensitive than business-oriented DSOsAlign deploying: DSO model expansion, targeted local marketing, brand strength, technology, and sales force proximity to retail doctorsEconomic confidence is primary limiting factor, but Align committing to active market development

Jason Bednar · Piper Sandler

China competitive landscape and VBP impact on go-to-market strategy; clarification on 'positioning'; hypothesis that U.S. retail weakness reflects selective customer vulnerability rather than broad consumer spending, and inquiry into effort defending lower-margin business while pursuing margin expansion targets

China VBP details still unclear on provinces/timing; no new news vs Q2. 'Positioning' means structuring portfolio for Tier 3/4 cities (emerging from private-patient focus in major cities). U.S. retail challenge reflects sophisticated DSOs implementing digital scanning, visualization, competitive pricing, and financing (HFD), outperforming less-organized retail doctors. Management sees market expansion opportunity (75% malinclusion untreated) rather than pure defense; DSOs winning through digital approach and patient-sensitivity, not price-cutting.

VBP implementation still uncertain on provinces and timelinePortfolio adaptation for Tier 3/4 China cities underway75% of population still has untreated malinclusionDSOs deploying: digital scanning, before/after visualization, competitive pricing, internal/external financing

Answers to last quarter's watch list

Clear Aligner volume growth turning negative. Resolved positively — volume came in at +4.9% YoY (647.8K cases), a clean acceleration from +0.3% in Q2, and management raised the FY guide from low-single to mid-single digits.

Resolved positively

Revenue per case trajectory. ASP came in at $1,245, down $5 QoQ and $30 YoY on geographic and product mix. Management says Q4 mix reverses as Europe's share grows, but the YoY $30 decline persists and is not yet showing signs of bottoming.

Resolved negatively

Q3 revenue vs $975M midpoint. Resolved positively — $995.7M revenue beat the $965–985M guide ($10.7M above the top of the range), with the volume re-acceleration doing the heavy lifting against weaker ASP.

Resolved positively

Restructuring charge containment within $150–170M. Management said restructuring is "nearing completion" without flagging overruns; the press release did not call out an expansion of the program. Status: Continue monitoring (need final Q4 charge detail).

North America and Western Europe stabilization. Resolved negatively — management explicitly characterized North America retail as "mixed" with no improvement quarter-to-quarter on gross receipts/CCA, and consumer confidence dropped further in September/October. DSO strength is masking retail rot.

Resolved negatively

FY26 ≥100bps operating margin improvement commitment. Reaffirmed in the press release, but management refused to bridge it to a 2026 top-line number when Joe Hogan pressed in Q&A. The commitment is intact; the credibility of the underlying math is the open question.

Continue monitoring

What to watch into next quarter

Q4 ASP actually reversing the QoQ decline. Management explicitly guided ASP up sequentially on favorable geographic mix. If Q4 ASP prints flat or down, the entire "geographic rotation" thesis breaks and the YoY price erosion looks structural rather than mix-driven.

Q4 revenue vs $1,025–1,045M. A miss would undermine the volume re-acceleration narrative; a beat with ASP confirmation would let Q3's volume guide raise stick as a genuine inflection.

North America retail showing any improvement in gross receipts or CCA. Management has now said two quarters running that it is unchanged. A third quarter of "no material change" makes this a structural call, not a macro one.

2026 revenue framing on the Q4 call. Management declined to provide 2026 specifics in Q3 Q&A. The Q4 call is when an FY26 reconciliation has to land. Watch whether the 100bps margin guide gets paired with a top-line range, and whether that range is inside the 5–15% LRP or below it.

Clear Aligner volume holding mid-single digits in Q4. The FY guide raise depends on Q4 not relapsing. Volume tracked +4.9% YoY in Q3 with Q4 guided "up sequentially" — anything below ~660K cases would put the FY raise at risk.

Restructuring final charge tally and FY26 cost-out attribution. With the program "nearing completion," Q4 should provide the closing charge number and the clearest read yet on how much of FY26's promised 100bps comes from cost cuts versus operating leverage.

Sources

Align Technology Q3 2025 earnings press release, October 29, 2025 — https://www.sec.gov/Archives/edgar/data/1097149/000109714925000075/algn-q325earningspressrele.htm
Align Technology Q3 2025 earnings call transcript (Q&A excerpts)
Align Technology Q2 2025 earnings press release (prior guidance baseline)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.